Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome



      The use of specific COX-2 inhibitors in cancer prevention has been associated with higher risk of acute coronary syndrome (ACS) and myocardial infarction. The aim of this study was to investigate if the polymorphisms COX2 T8473C (rs5275), and COX2 A-1195G (rs689466), which modify the enzyme levels of COX-2, were associated with risk of ACS and if alcohol intake, smoking, and use of NSAID would modify the associations. We also wanted to investigate associations with blood lipid levels.


      A case–cohort study including 1031 ACS cases and a sub-cohort of 1703 persons was nested within the population-based prospective study Diet, Cancer and Health of 57,053 individuals aged 55–64 at recruitment 1993–1997.


      Male variant allele carriers of COX-2 T8473C were at lower risk of ACS (IRR = 0.75, CI = 0.61–0.93, p = 0.008) than homozygous wildtype carriers. There were no statistically significant interactions between genotypes and alcohol intake, smoking and NSAID use in relation to risk of ACS. Among males, there was interaction between COX-2 T8473C and alcohol in relation to total cholesterol, non-HDL cholesterol and LDL levels (p for interaction: 0.003, 0.007 and 0.01, respectively), such that variant allele carriers with low alcohol intake had the lowest lipid levels. No statistically significant associations were observed in females.


      This study suggests that genetically determined COX-2 levels are associated with risk of ACS and blood lipid levels among males. No consistent associations were found for females.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Krotz F.
        • Schiele T.M.
        • Klauss V.
        • Sohn H.Y.
        Selective COX-2 inhibitors and risk of myocardial infarction.
        J Vasc Res. 2005; 42: 312-324
        • Sanak M.
        • Szczeklik W.
        • Szczeklik A.
        Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma.
        J Allergy Clin Immunol. 2005; 116: 221-223
        • Zhang X.
        • Miao X.
        • Tan W.
        • et al.
        Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.
        Gastroenterology. 2005; 129: 565-576
        • Martey C.A.
        • Pollock S.J.
        • Turner C.K.
        • et al.
        Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
        Am J Physiol Lung Cell Mol Physiol. 2004; 287: L981-L991
        • Mustonen H.
        • Hietaranta A.
        • Puolakkainen P.
        • et al.
        Ethanol induced NF-{kappa}B activation protects against cell injury in cultured rat gastric mucosal epithelium.
        Am J Physiol Gastrointest Liver Physiol. 2007; 292: G1614-G1621
        • Tipoe G.L.
        • Liong E.C.
        • Casey C.A.
        • et al.
        A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury.
        Alcohol Clin Exp Res. 2008; 32: 669-682
        • Yuan C.J.
        • Mandal A.K.
        • Zhang Z.
        • Mukherjee A.B.
        Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs.
        Cancer Res. 2000; 60: 1084-1091
        • Ramsay R.G.
        • Friend A.
        • Vizantios Y.
        • et al.
        Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB.
        Cancer Res. 2000; 60: 1805-1809
        • Chan E.S.
        • Zhang H.
        • Fernandez P.
        • et al.
        Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk.
        Arthritis Res Ther. 2007; 9: R4
        • Narasimha A.
        • Watanabe J.
        • Lin J.A.
        • et al.
        A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitors.
        Prostaglandins Other Lipid Mediat. 2007; 84: 24-33
        • Tjonneland A.
        • Olsen A.
        • Boll K.
        • et al.
        Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark.
        Scand J Public Health. 2007; 35: 432-441
        • Barlow W.E.
        • Ichikawa L.
        • Rosner D.
        • Izumi S.
        Analysis of case–cohort designs.
        J Clin Epidemiol. 1999; 52: 1165-1172
        • Joensen A.M.
        • Jensen M.K.
        • Overvad K.
        • et al.
        Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry.
        J Clin Epidemiol. 2009; 62: 188-194
        • Jensen M.K.
        • Rimm E.B.
        • Rader D.
        • et al.
        S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies.
        Am Heart J. 2009; 157: 384-390
        • Jensen M.K.
        • Rimm E.B.
        • Mukamal K.J.
        • et al.
        The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations.
        Eur Heart J. 2009; 30: 1584-1589
        • Vogel U.
        • Segel S.
        • Dethlefsen C.
        • et al.
        PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes.
        BMC Med Genet. 2009; 10: 52
        • Tolstrup J.S.
        • Jensen M.K.
        • Tjonneland A.
        • Overvad K.
        • Gronbaek M.
        Drinking pattern and mortality in middle-aged men and women.
        Addiction. 2004; 99: 323-330
        • Miller S.A.
        • Dykes D.D.
        • Polesky H.F.
        A simple salting out procedure for extracting DNA from human nucleated cells.
        Nucleic Acids Res. 1988; 16: 1215
        • Vogel U.
        • Christensen J.
        • Wallin H.
        • et al.
        Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes.
        Mutat Res. 2007; 617: 138-146
        • Campa D.
        • Zienolddiny S.
        • Maggini V.
        • et al.
        Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.
        Carcinogenesis. 2004; 25: 229-235
        • Kalbfleisch J.D.
        • Lawless J.F.
        Likelihood analysis of multi-state models for disease incidence and mortality.
        Stat Med. 1988; 7: 149-160
        • Vogel U.
        • Christensen J.
        • Wallin H.
        • et al.
        Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study.
        Mutat Res. 2008; 639: 89-100
        • Vogel U.
        • Christensen J.
        • Dybdahl M.
        • et al.
        Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer.
        Mutat Res. 2007; 624: 88-100
        • Hansen R.D.
        • Sorensen M.
        • Tjonneland A.
        • et al.
        XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer.
        Mutat Res. 2007; 619: 68-80
        • Hansen R.D.
        • Sorensen M.
        • Tjonneland A.
        • et al.
        A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case–cohort study.
        BMC Cancer. 2008; 8: 54
        • Hansen R.D.
        • Krath B.N.
        • Frederiksen K.
        • et al.
        GPX1 Pro(198)Leu polymorphism, erythrocyte GPX activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer.
        Mutat Res. 2009; 664: 13-19
        • Raaschou-Nielsen O.
        • Sorensen M.
        • Hansen R.D.
        • et al.
        GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer.
        Cancer Lett. 2007; 247: 293-300
        • Vogel U.
        • Sorensen M.
        • Hansen R.D.
        • et al.
        Gene–environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study.
        Cancer Lett. 2007; 247: 159-165
        • Perneger T.V.
        What's wrong with Bonferroni adjustments.
        BMJ. 1998; 316: 1236-1238
        • Bonaterra G.A.
        • Hildebrandt W.
        • Bodens A.
        • et al.
        Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects.
        Free Radic Biol Med. 2005; 38: 235-242
        • Vinals M.
        • Martinez-Gonzalez J.
        • Badimon J.J.
        • Badimon L.
        HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2).
        Arterioscler Thromb Vasc Biol. 1997; 17: 3481-3488
        • Szczeklik W.
        • Sanak M.
        • Rostoff P.
        • et al.
        Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease.
        Thromb Haemost. 2008; 100: 893-898
        • Cipollone F.
        • Toniato E.
        • Martinotti S.
        • et al.
        A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.
        JAMA. 2004; 291: 2221-2228
        • Lee C.R.
        • North K.E.
        • Bray M.S.
        • et al.
        Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
        Clin Pharmacol Ther. 2008; 83: 52-60
        • Kohsaka S.
        • Volcik K.A.
        • Folsom A.R.
        • et al.
        Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.
        Atherosclerosis. 2008; 196: 926-930
        • Chang L.W.
        • Chang Y.C.
        • Ho C.C.
        • Tsai M.H.
        • Lin P.
        Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol.
        Carcinogenesis. 2007; 28: 1606-1612
        • Norata G.D.
        • Tibolla G.
        • Seccomandi P.M.
        • Poletti A.
        • Catapano A.L.
        Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells.
        J Clin Endocrinol Metab. 2006; 91: 546-554